Surgery Partners (SGRY) Cash & Equivalents (2013 - 2026)

Surgery Partners' Cash & Equivalents history runs 14 years deep, the most recent figure standing at $182.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 20.5% year-over-year to $182.3 million; the TTM figure through Mar 2026 stood at $182.3 million (down 20.5% YoY), while the FY2025 annual figure was $239.9 million, down 10.98% from the prior year.
• Cash & Equivalents came in at $182.3 million for Q1 2026 at Surgery Partners, down from $239.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $378.9 million in Q1 2022 to a low of $154.8 million in Q3 2022.
• A 5-year average of $229.0 million and a median of $227.4 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 53.15% in 2022 and jumped 52.45% in 2023, its largest moves.
• Surgery Partners' Cash & Equivalents stood at $282.9 million in 2022, then sank by 30.75% to $195.9 million in 2023, then surged by 37.57% to $269.5 million in 2024, then declined by 10.98% to $239.9 million in 2025, then dropped by 24.01% to $182.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $182.3 million, $239.9 million, and $203.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison